STAT+: Eli Lilly says it will hike list prices for drugs abroad. Now what?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning. Today, we see march-in rights return to the headlines, ponder how Eli Lilly’s plan to hike list prices in Europe may play out, and more.

Trump administration puts focus on march-in rights

The Trump administration recently threatened to invoke a controversial provision of the Bayh-Dole Act to potentially seize and relicense Harvard University patents stemming from federally funded research, accusing the school of breaching disclosure and licensing rules. A letter from Commerce Secretary Howard Lutnick signaled a “march-in” review — a power never used before — which is being viewed by some as political retribution.

Continue to STAT+ to read the full story…